Focus Partners Wealth
PRLD icon

Focus Partners Wealth’s Prelude Therapeutics PRLD Stock Holding History

Focus Partners Wealth’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$171K Hold
50,007
– – ﹤0.01% 2444
2025
Q4 		$145K Buy
+50,007
New +$84.4K ﹤0.01% 2500

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Focus Partners Wealth's PRLD Position: Q1 2026 in Review

Focus Partners Wealth held its Prelude Therapeutics (PRLD) position steady in Q1 2026 at 50,007 shares worth $171K. The position accounts for ﹤0.01% of the portfolio, ranked #2444.

Focus Partners Wealth first reported a position in PRLD in Q4 2025 and has held it in 2 quarters since. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Focus Partners Wealth held 50,007 shares of Prelude Therapeutics worth $171K as of Q1 2026.
  • Focus Partners Wealth left its Prelude Therapeutics share count unchanged in Q1 2026.
  • Prelude Therapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q1 2026, its #2444 holding.
  • Focus Partners Wealth first reported a position in Prelude Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.